Business Wire India
  • Pfizer’s PCV 13 vaccine selected for inclusion in expansion of India’s immunization program. Phase 1 immunization program to cover 20% of around 26 million children [1] of India’s birth cohort under the Gavi funded program
neumococcal disease is one of the leading causes of deaths in children younger than 5 years of age. In India, according to the Farooqui article published in 2015, approximately 105,000 children had died of pneumococcal pneumonia in 2010.S. Sridhar, Country Manager, Pfizer India.Pfizer Vaccines in the Developing World®® About Prevenar 13 ®                                                                                                                               ®®®® Pfizer Inc.: Working together for a healthier world ®
[2]   PneumoNET, PIDOPS and ASIP studies
comment COMMENT NOW